Since HLA-DRB1*07:01 is associated with lapatinib-induced hepatotoxicity, genetic screening of HLA-DRB1*07:01 in breast cancer patients prior to lapatinib therapy is warranted for patient safety.
Our results present the first NY-BR-1-specific HLA-DRB1*0301- and HLA-DRB1*0401-restricted T cell epitopes that could be exploited for therapeutic intervention against breast cancer.
In the literature, data concerning the relationship between breast cancer and HLA class II gene polymorphisms are limited, so the aim of this study was to determine if HLA-DQB1 and HLA-DRB1 MHC class-II alleles may confer susceptibility or resistance to the disease among Jordanian females.
As a result, while HLA-DRB1 03, HLA-DQB1 02, HLA-DRB1 13, and HLA-DQB1 06 alleles were found to be involved in protectiveness against breast cancer and good prognosis; HLA-DQB1 03 and HLA-DRB1 04 alleles were found to be involved in poor prognosis.